Gland Pharma Limited (GLAND.NS)
INR 1764.95
(0.06%)
INR 1764.95
(0.06%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | 46.90 INR | -1.14% |
| 2022 | 47.44 INR | -35.73% |
| 2021 | 73.81 INR | 17.03% |
| 2020 | 63.07 INR | 26.44% |
| 2019 | 49.88 INR | 80.27% |
| 2018 | 27.67 INR | 40.74% |
| 2017 | 19.66 INR | -26.37% |
| 2016 | 26.70 INR | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q1 | 8.73 INR | -25.26% |
| 2024 Q2 | 9.93 INR | 13.75% |
| 2023 FY | - INR | -1.14% |
| 2023 Q2 | 11.78 INR | -0.08% |
| 2023 Q3 | 11.65 INR | -1.1% |
| 2023 Q1 | 11.79 INR | 146.65% |
| 2023 Q4 | 11.68 INR | 0.26% |
| 2022 Q1 | 13.93 INR | -19.94% |
| 2022 FY | - INR | -35.73% |
| 2022 Q4 | 4.78 INR | -66.05% |
| 2022 Q3 | 14.08 INR | -3.89% |
| 2022 Q2 | 14.65 INR | 5.17% |
| 2021 FY | - INR | 17.03% |
| 2021 Q4 | 17.40 INR | 4.69% |
| 2021 Q3 | 16.62 INR | -9.53% |
| 2021 Q2 | 18.37 INR | -14.2% |
| 2021 Q1 | 21.41 INR | 30.79% |
| 2020 Q1 | 19.21 INR | 61.02% |
| 2020 Q2 | 13.40 INR | -30.24% |
| 2020 Q3 | 12.83 INR | -4.25% |
| 2020 FY | - INR | 26.44% |
| 2020 Q4 | 16.37 INR | 27.59% |
| 2019 FY | - INR | 80.27% |
| 2019 Q4 | 11.93 INR | 26.38% |
| 2019 Q3 | 9.44 INR | 0.0% |
| 2019 Q1 | 11.25 INR | 0.0% |
| 2018 FY | - INR | 40.74% |
| 2017 FY | - INR | -26.37% |
| 2016 FY | - INR | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| Abbott India Limited | 565.30 INR | 91.704% |
| Cipla Limited | 51.05 INR | 8.129% |
| GlaxoSmithKline Pharmaceuticals Limited | 34.83 INR | -34.654% |
| Kopran Limited | 10.57 INR | -343.709% |
| Marksans Pharma Limited | 6.92 INR | -577.746% |
| NGL Fine-Chem Limited | 66.88 INR | 29.874% |
| Pfizer Limited | 120.51 INR | 61.082% |
| Sanofi India Limited | 261.78 INR | 82.084% |
| SMS Pharmaceuticals Limited | 5.89 INR | -696.265% |
| TTK Healthcare Limited | 44.47 INR | -5.464% |